- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06324071
Study to Verify the Efficacy of a Product Containing 125 mg of TetraSOD® for the Treatment of Male Infertility
A Double-blind Randomized Placebo-controlled Clinical Study to Verify the Efficacy of TetraSOD® in the Improvement of Semen Quality in Patients With iIdiopathic Infertility
Study Overview
Status
Conditions
Detailed Description
Infertility is an increasing global public health problem present in about 15-20% of the population of reproductive age, affecting as many as 186 million people worldwide. A male factor is present in approximately 50% of the infertile couples, a large number of them of unknown or idiopathic origin.
Spermatogenesis is a complex biological process that requires a highly regulated genetic and hormonal program in a singular environment created by the interaction with different cell types to orchestrate a successful differentiation process. This process occurs periodically every 72 days during a man's fertile life. It has been demonstrated that semen quality is deteriorating over the time, perhaps as a result of exposition to several environmental factors related with lifestyle: drug use (such us tobacco, alcohol, marijuana, cocaine, opioids and anabolic agents), diet and overweight, disorders of the sleep-wake cycle and working conditions (continuous exposition to heat sources or toxic substances) that could impact both directly and indirectly on the complex process of spermatogenesis.
Currently, the impact of oxidative stress, a cellular state product of an imbalance between the generation of highly unstable molecules known as reactive oxygen species (ROS) and the antioxidant cellular capacity in male fertility is being deeply investigated. High levels of oxidative stress in semen have been associated with both lower sperm concentration, sperm motility and acrosome integrity and higher sperm DNA damage and mitochondrial activity. Recent clinical trials have demonstrated the high prevalence of sperm DNA damage by up to 80% of men diagnosed with idiopathic male infertility. This DNA damage produced during spermatogenesis or sperm maturation process could be the result of an increase of reactive oxygen species (ROS) in male reproductive tract, which are related to different known factors (chronic systemic disease, use of some drugs, radiation or pesticides, febrile processes, old age and environmental factors related to lifestyle: smoking, obesity, alcohol) and other unknown so far.
Antioxidant supplementation has gained relevance within routine practices in patients with reproductive problems. Different studies have shown the beneficial effect of antioxidant consumption against oxidative damage caused by environmental and pathological components, improving sperm characteristics associated with the seminal analysis. There are scientific evidences about the improvement of male fertility and higher rates of live newborn after antioxidant treatment in subfertile men.
TetraSOD® is a unique commercial product comprised of 100% lyophilized biomass of the marine microalgae Tetraselmis chuii strain CCFM03, which is currently marketed for food and nutraceutical applications around the world by the company Fitoplancton Marino, S.L. This microalgae product is characterized by a high content in the antioxidant enzyme superoxide dismutase (SOD), as it is produced using own (patent pending) technology developed by the company. Results of in vitro studies with human cell lines suggest that TetraSOD® stimulates the cellular protective mechanisms against oxidative stress. Moreover, results previously obtained in a pilot study with the highest dose of TetraSOD® (250 mg/day) were promising, since a high statistically significant response was observed in three of the four studied parameters after three months of treatment.
Taking into account these results, a new extended double-blind randomized and placebo-controlled clinical study has been performed to confirm the positive effects of dietary supplementation with 250 mg of TetraSOD® during 3 months (corresponding to the time of a complete spermatogenic cycle) in sperm quality.
The main objective of this new study is to check the usefulness of a lower dose of TetraSOD® (125 mg/day) in the improvement of sperm quality, including sperm DNA fragmentation. As previously mentioned, oxidative stress is one of the main causes of sperm DNA damage. Nowadays, a diagnostic test for the study of the sperm DNA fragmentation exists, but it requires a specific sperm sample processing and the results are obtained in delay-time. In this new trial, correlation between sperm DNA fragmentation and static oxidation reduction potential (sORP) degree by the use of the Male Infertility Oxidative System (MiOXSYS) will be also tested as in the previous one with a higher dose of TetraSOD® (250 mg/day). Classical seminal parameters (semen volume, sperm concentration and number, sperm progressive motility) will be also quantified. In that way, with this new trial it will be possible to determine a range of TetraSOD® dosage being clinically active for the treatment of male infertility.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Carlos Infante
- Phone Number: +34 956561079
- Email: carlos.infante@easyalgae.com
Study Contact Backup
- Name: Carlos Unamunzaga
- Phone Number: +34 956561079
- Email: cue@easyalgae.com
Study Locations
-
-
-
Barcelona, Spain, 08036
- Recruiting
- Hospital Clínic
-
Contact:
- Juan M Corral
- Phone Number: +34 932275545
- Email: jmcorral@clinic.cat
-
Contact:
- Meritxell Jodar
- Phone Number: +34 932275510
- Email: mjodar@clinic.cat
-
Sub-Investigator:
- Marta Guimerà
-
Sub-Investigator:
- Juan M Mayorga-Torres
-
Sub-Investigator:
- Antonio Alcaraz
-
Sub-Investigator:
- Dolors Manau
-
Sub-Investigator:
- Rafael Oliva
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Age: 18 to 45
- Male patients with idiopathic infertility classified with asthenozoospermia, oligozoospermia or oligoasthenozoospermia after seminal assessment.
- Not achieving pregnancy after at least one year of intercourse with the same partner without protective measures
Exclusion Criteria:
- Azoospermia (absence of spermatozoa) or severe oligozoospermia (< 5 x 10^6 spermatozoa/ml of ejaculate)
- Testicular torsion or prostatitis
- Urinary retention and infections
- Drug consumption
- Hormone treatments
- Recent surgical interventions
- Diabetes
- Kidney or liver disease
- Leukocytosis
- Antioxidant supplement consumption in the last 3 months
- BMI>30 Kg/m2
- Endocrinopathies, hypo and hyperthyroidism
- Chromosomal anomalies (XX, XYY, XXY)
- Treatments with anticoagulants
- Radiotherapy/Chemotherapy
- Participation in another clinical study prior to inclusion in this study that could affect the objectives of the current study
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Control group
Group supplemented with a daily dose of placebo
|
Participants in the Control group will receive a daily dose of placebo in a capsule during 90 days.
|
Experimental: Experimental group
Group supplemented with 125 mg/day of TetraSOD®
|
Participants in the Experimental group will receive a daily dose of 125 mg of TetraSOD® in a capsule during 90 days.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Sperm concentration
Time Frame: 90 days
|
Sperm concentration will be determined according to the method described in the WHO laboratory manual for the examination and processing of human semen, 5th ed.
Geneva: World Health Organization (2010)
|
90 days
|
Sperm oxidative stress
Time Frame: 90 days
|
Sperm ROS intracellular will be measured by flow cytometry evaluating the sperm intracellular ROS (superoxide anion, hydroxyl radical, hydrogen peroxide)
|
90 days
|
Sperm motility
Time Frame: 90 days
|
Sperm motility will be assessed according to the method described in the World Health Organization (WHO) laboratory manual for the examination and processing of human semen, 5th ed.
Geneva: World Health Organization (2010)
|
90 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
DNA integrity
Time Frame: 90 days
|
DNA integrity/fragmentation will be evaluated using the COMET assay
|
90 days
|
Adverse effects
Time Frame: 90 days
|
Any kind of adverse event attributable to TetraSOD® will be recorded during the duration of the trial
|
90 days
|
sORP by MiOXSYS
Time Frame: 90 days
|
sORP will be also assessed using the MiOXSYS system
|
90 days
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Juan M Corral, Hospital Clinic Barcelona, Spain
- Principal Investigator: Meritxell Jodar, Hospital Clinic Barcelona, Spain
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2022_TSOD_125
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Male Infertility
-
University of WashingtonEunice Kennedy Shriver National Institute of Child Health and Human Development...CompletedMale Infertility, AzoospermiaUnited States
-
Assuta Hospital SystemsMaccabi Healthcare Services, IsraelCompletedInfertility, Female Infertility, Male InfertilityIsrael
-
Reproductive Medicine Associates of New JerseyTerminated
-
Jinling Hospital, ChinaRecruitingMale Infertility Due to HypospermatogenesisChina
-
Sapientiae InstituteTerminated
-
Radboud University Medical CenterZonMw: The Netherlands Organisation for Health Research and DevelopmentCompletedPregnancy | Male Infertility | Female InfertilityNetherlands
-
Gazi UniversityCompletedMale Infertility | Unexplained Infertility
-
Hillel Yaffe Medical CenterUnknownMale Infertility With Severe Oligo-terato-asteno-spermiaIsrael
-
Assiut UniversityNot yet recruitingMale Infertility Due to Azoospermia
-
Universitair Ziekenhuis BrusselRecruitingMale InfertilityBelgium
Clinical Trials on Sham
-
Universidad de AlmeriaSecretaría General de Universidades, Investigación y Tecnología, Junta de...Enrolling by invitationSubstance-Related DisordersSpain
-
Instituto Mexicano del Seguro SocialInstituto Nacional de Salud Publica, Mexico; Universidad Nacional Autonoma... and other collaboratorsRecruitingEffect of Electroacupuncture on Sensitive Symptoms of Distal Diabetic Peripheral Neuropathy (EA&DPN)Diabetic Peripheral Neuropathic Pain | Diabetic Peripheral Neuropathy | Acupuncture | Diabetic Polyneuropathy | Electroacupuncture | Nerve ConductionMexico
-
University of LeipzigReCor Medical, Inc.RecruitingHeart Failure With Preserved Ejection Fraction | Hypertension, RenalGermany
-
Institut National de la Santé Et de la Recherche...Centre Hospitalier Régional Universitaire MontpellierCompletedChronic Obstructive Pulmonary Disease
-
Corporacion Parc TauliCompletedFatigue | Inflammatory Bowel DiseaseSpain
-
Oulu University HospitalLoisto Terveys, Oulu; Fysios Kastelli, Oulu; Faskia-Markus, OuluEnrolling by invitationLow Back Pain | Low Back Pain, RecurrentFinland
-
Medical University of South CarolinaCompletedUse of Novel Sinusonic Device for Prevention of Community Acquired Upper Respiratory Infection (URI)Upper Respiratory InfectionUnited States
-
Istituto Superiore di Osteopatia di MilanoCompletedHealthy | Osteopathic ManipulationItaly
-
Phramongkutklao College of Medicine and HospitalUnknownIschemic Reperfusion InjuryThailand